Effectiveness of Gemcitabine with or without Radiotherapy in Gallbladder Carcinoma: Gemcitabine in Gallbladder Carcinoma

Asima Luqman

doi:10.54393/pjhs.v5i12.1989

Authors

Asima Luqman Department of Radiotherapy, Quaid e Azam Medical College, Bahawalpur, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i12.1989

Keywords:

Carcinoma, Chemotherapy, Gallbladder, Gemcitabine, Radiotherapy, Karnofsky performance score

Abstract

Gallbladder carcinoma is the most common malignancy of the hepatobiliary tract and the 5^th most common cancer of the gastrointestinal tract. Objective: To compare the efficacy of gemcitabine as a single agent or in combination with radiation in terms of response rate and relief of symptoms in gallbladder carcinoma. Methods: This retrospective study was accomplished at the department of oncology, Nishter Hospital Multan, Pakistan, from January 2021 to December 2022. Inclusion criteria were patients with a histopathologically proven diagnosis of gallbladder carcinoma, and they were advised gemcitabine with or without radiation therapy as per the treating physician’s discretion. The treatment response rate and alleviation of symptoms were noted. Results: Among a total of 50 patients, 40 (80.0%) were female. The mean age was 56.58 ± 6.14 years. At baseline, 33 (66.0%) patients had stable disease, while the remaining 17 (34.0%) had progressive disease. Gemcitabine alone revealed stable disease, and progressive disease in 14 (56.0%), and 11 (44.0%) patients, respectively, whereas among patients receiving gemcitabine plus radiotherapy, partial response, stable disease, and progressive disease were observed in 7 (28.0%), 14 (50.0%), and 4 (16.0%) patients, respectively (p=0.006). Regarding symptom relief, 8 (32.0%) patients in the gemcitabine alone group had pain relief versus 20 (80.0%) in the gemcitabine plus radiotherapy group (p=0.001). Conclusion: Gemcitabine plus concomitant radiotherapy was more effective in achieving higher response rates and alleviation of symptoms when compared to gemcitabine alone in gallbladder carcinoma patients.

References

Okumura K, Gogna S, Gachabayov M, Felsenreich DM, McGuirk M, Rojas A et al. Gallbladder cancer: Historical treatment and new management options. World Journal of Gastrointestinal Oncology. 2021 Oct; 13(10): 1317. doi: 10.4251/wjgo.v13.i10.1317.

Li ZZ, Guan LJ, Ouyang R, Chen ZX, Ouyang GQ, Jiang HX. Global, regional, and national burden of gallbladder and biliary diseases from 1990 to 2019. World Journal of Gastrointestinal Surgery. 2023 Nov; 15(11): 2564. doi: 10.4240/wjgs.v15.i11.2564.

Bojan A, Foia LG, Vladeanu MC, Bararu Bojan I, Plesoianu C, Plesoianu A et al. Understanding the mechanisms of gallbladder lesions: A systematic review. Experimental and Therapeutic Medicine. 2022 Jul; 24(3): 604. doi: 10.3892/etm.2022.11541.

Teng TZ, Chua BQ, Shelat VG. Carcinosarcoma of gallbladder: a world review. World Journal of Clinical Oncology. 2021 Dec; 12(12): 1244. doi: 10.5306/wjco.v12.i12.1244.

Al Jaber F, Almaher E, Al-Ibrahim R, AlQahtani M. Curative surgical resection for initially unresectable metastatic gallbladder cancer following neoadjuvant chemotherapy: Case report and review of literature. International Journal of Surgery Case Reports. 2022 Nov; 100: 107694. doi: 10.1016/j.ijscr.2022.107694.

Stinton LM and Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut and liver. 2012 Apr; 6(2): 172. doi: 10.5009/gnl.2012.6.2.172.

Pérez-Moreno P, Riquelme I, García P, Brebi P, Roa JC. Environmental and lifestyle risk factors in the carcinogenesis of gallbladder cancer. Journal of Personalized Medicine. 2022 Feb; 12(2): 234. doi: 10.3390/jpm12020234.

Hu ZI and Lim KH. Evolving paradigms in the systemic treatment of advanced gallbladder cancer: updates in year 2022. Cancers. 2022 Feb; 14(5): 1249. doi: 10.3390/cancers14051249.

Shao J, Lu HC, Wu LQ, Lei J, Yuan RF, Shao JH. Simple cholecystectomy is an adequate treatment for grade I T1bN0M0 gallbladder carcinoma: Evidence from 528 patients. World Journal of Gastroenterology. 2022 Aug; 28(31): 4431. doi: 10.3748/wjg.v28.i31.4431.

Pahlajani NH, Ruth KJ, Freedman GM, Meropol NJ, Cohen SJ, Watson JC et al. Radiation therapy in gallbladder cancer treatment: the Fox Chase Cancer Center experience. International Journal of Radiation Oncology, Biology, Physics. 2007 Nov; 69(3): S301. doi: 10.1016/j.ijrobp.2007.07.1351.

Vergara-Gómez L, Bizama C, Zhong J, Buchegger K, Suárez F, Rosa L et al. A novel gemcitabine-resistant gallbladder cancer model provides insights into molecular changes occurring during acquired resistance. International Journal of Molecular Sciences. 2023 Apr; 24(8): 7238. doi: 10.3390/ijms24087238.

Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). Journal of Hepato-Biliary-Pancreatic Sciences. 2023 Jan; 30(1): 102-110. doi: 10.1002/jhbp.1219.

Boxberger F, Jüngert B, Brueckl V, Brueckl WM, Hautmann M, Hohenberger W et al. Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas. Anti-Cancer Drugs. 2003 Jan; 14(1): 87-90. doi: 10.1097/00001813-200301000-00012.

Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Annals of Oncology. 2001 Feb; 12(2): 183-6. doi: 10.1023/A:1008352123009.

Kumar D, Kiran NM, Khosla D. Reviewing the potential role of radiation therapy in gallbladder cancer: an update. Radiation Oncology Journal. 2022 Mar; 40(1): 1. doi: 10.3857/roj.2021.00717.

Agrawal S, Gupta A, Kapoor V, Rahul R, Singh A, Mishra P et al. Predictors of Toxicity in a Randomized Study of Consolidation Chemoradiation Versus Observation After First Line Chemotherapy in Advanced Gall Bladder Cancers. Advances in Radiation Oncology. 2024 May; 9(5): 101468. doi: 10.1016/j.adro.2024.101468.

Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clinical and Experimental Hepatology. 2019 May; 5(2): 93-102. doi: 10.5114/ceh.2019.85166.

Sturm N, Schuhbaur JS, Hüttner F, Perkhofer L, Ettrich TJ. Gallbladder cancer: current multimodality treatment concepts and future directions. Cancers. 2022 Nov; 14(22): 5580. doi: 10.3390/cancers14225580.

Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Investigational New Drugs. 2004 Apr; 22: 193-8. doi: 10.1023/B:DRUG.0000011797.09549.53.

Gong L, Zhang Y, Liu C, Zhang M, Han S. Application of radiosensitizers in cancer radiotherapy. International Journal of Nanomedicine. 2021 Feb: 1083-102. doi: 10.2147/IJN.S290438.

Yuan Z, Shui Y, Liu L, Guo Y, Wei Q. Postoperative recurrent patterns of gallbladder cancer: possible implications for adjuvant therapy. Radiation Oncology. 2022 Jul; 17(1): 118. doi: 10.1186/s13014-022-02091-6.

Kang S, Yoo C, Lee SH, Oh D, Song TJ, Lee SS et al. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology. 2022 May; 14: 17588359221097190. doi: 10.1177/17588359221097190.

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Journal of the American Medical Association. 2007 Jan; 297(3): 267-77. doi: 10.1001/jama.297.3.267.

Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for biliary tract cancer in 2021. Journal of Clinical Medicine. 2021 Jul; 10(14): 3108. doi: 10.3390/jcm10143108.